Novartis's secukinumab leads anti-IL17 charge in psoriasis
This article was originally published in Scrip
Detailed results from Novartis's key Phase III FIXTURE study that pitted its investigational product secukinumab against current biological mainstay Enbrel (etanercept) in psoriasis suggest the product could prove a robust challenger to current treatments.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.